HC Wainwright Expects Stronger Earnings for Alpha Cognition

Alpha Cognition, Inc. (NASDAQ:ACOG) – HC Wainwright increased their Q1 2025 earnings estimates for shares of Alpha Cognition in a report released on Monday, March 31st. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.38) per share for the quarter, up from their previous estimate of ($0.72). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock.

Separately, Raymond James raised shares of Alpha Cognition to a “moderate buy” rating in a research note on Tuesday, March 25th.

Alpha Cognition Price Performance

NASDAQ ACOG opened at $4.83 on Thursday. The stock’s 50-day simple moving average is $5.73. Alpha Cognition has a twelve month low of $4.28 and a twelve month high of $7.00. The stock has a market capitalization of $77.38 million, a P/E ratio of -1.89 and a beta of 2.50.

Alpha Cognition (NASDAQ:ACOG) last announced its quarterly earnings data on Monday, March 31st. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.03).

Hedge Funds Weigh In On Alpha Cognition

A number of hedge funds have recently made changes to their positions in the stock. Sphera Funds Management LTD. acquired a new stake in shares of Alpha Cognition during the 4th quarter worth $3,652,000. Bleichroeder LP purchased a new stake in Alpha Cognition during the fourth quarter valued at about $1,024,000. Alyeska Investment Group L.P. acquired a new stake in Alpha Cognition during the fourth quarter worth about $2,356,000. Manatuck Hill Partners LLC acquired a new stake in Alpha Cognition during the fourth quarter worth about $395,000. Finally, Tudor Investment Corp ET AL purchased a new position in shares of Alpha Cognition in the 4th quarter worth about $412,000.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.